RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants

Liang, Qingtai; Wang, Yifeng; Zhang, Shuyuan; Sun, Jing; Sun, Wei; Li, Jizhou; Liu, Yaping; Li, Mingxi; Cheng, Lin; Jiang, Yuhang; Wang, Ruoke; Zhang, Rui; Yang, Zihan; Ren, Yifei; Chen, Peng; Gao, Peng; Yan, Huayuan; Zhang, Zheng; Zhang, Qi; Shi, Xuanling; Wang, Jianbin; Liu, Wanli; Wang, Xinquan; Ying, Bo; Zhao, Jincun; Qi, Hai; Zhang, Linqi

doi:10.1016/j.isci.2022.104043

Cited by 24 publications

(17 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data therefore suggest that other elements of mRNA design, not the chemical modification, could be involved in the observed immunogenic effects. Other studies performed in non-human primates have also showed that the optimization of non-coding mRNA elements could improve the immunogenicity and protective efficacy of mRNA vaccines [ 29 , 30 ]. This could be the case for TMEP-B mRNA in this research.…”

Section: Discussionmentioning

confidence: 99%

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

et al. 2023

View full text Add to dashboard Cite

The development of new strategies to achieve a functional cure for HIV remains a priority. We tested a novel HIV therapeutic vaccine using unmodified mRNA (TMEP-B) and mRNA modified by 1-methyl-3′-pseudouridylyl (TMEP-Bmod) expressing both a multiepitopic sequences from Gag, Pol, and Nef proteins, including different CD4 and CD8 T-cell epitopes functionally associated with HIV control in transfected monocyte-derived dendritic cells (MDDCs) obtained from HIV infected patients. In vitro assays were used to test the mRNAs alone and in combination with immunomodulator agents, such as the TLR-7 agonist Vesatolimod and the PD-1 antagonist Nivolumab to try to improve HIV-specific cellular immune responses. Combining the mRNAs with the immunomodulators enhanced HIV-specific T-cell responses, together with the secretion of IFNγ, IP10, MIP-1α, and MIP-1β, which are fundamental mediators of viral control. Our data suggest that the mRNA vaccine prototypes TMEP-B and TMEP-Bmod, when combined with Vesatolimod and/or Nivolumab, could achieve functional cure for patients with HIV.

show abstract

Section: Discussionmentioning

confidence: 99%

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Preserving membrane-binding features could inform the development of vaccines. For example, those based on stabilized RBD trimers (Liang et al, 2022a(Liang et al, , 2022bMalladi et al, 2021;Routhu et al, 2021) could be designed to maintain the integrity of the spike's dominant RBM membrane-binding surface for inducing potently neutralizing antibodies. While monomeric and dimeric RBD-based vaccines are also in development, these offer smaller membrane-binding surfaces that diverge from the native closed state.…”

Section: Discussionmentioning

confidence: 99%

Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins

2022

View full text Add to dashboard Cite

“…The mapped epitopes were compared with those deposited in the GISAID database. The analysis revealed a high degree of conservation of the mapped epitope among SARS-CoV-2 variants [ 143 ]. Table 2 displays a list of some epitope-based vaccine studies, techniques used, and study outcomes.…”

Section: Applications Of Epitope Mapping In Covid-19mentioning

confidence: 99%

State of the Art in Epitope Mapping and Opportunities in COVID-19

et al. 2023

View full text Add to dashboard Cite

The understanding of any disease calls for studying specific biological structures called epitopes. One important tool recently drawing attention and proving efficiency in both diagnosis and vaccine development is epitope mapping. Several techniques have been developed with the urge to provide precise epitope mapping for use in designing sensitive diagnostic tools and developing rpitope-based vaccines (EBVs) as well as therapeutics. In this review, we will discuss the state of the art in epitope mapping with a special emphasis on accomplishments and opportunities in combating COVID-19. These comprise SARS-CoV-2 variant analysis versus the currently available immune-based diagnostic tools and vaccines, immunological profile-based patient stratification, and finally, exploring novel epitope targets for potential prophylactic, therapeutic or diagnostic agents for COVID-19.

show abstract

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants

Cited by 24 publications

References 52 publications

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins

State of the Art in Epitope Mapping and Opportunities in COVID-19

Contact Info

Product

Resources

About